Trial to Promote Recovery From COVID-19 With Endocrine Therapy
Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Patients with COVID-19 requiring inpatient hospitalization will be randomized to treatment
with standard of care or standard of care + bicalutamide. This will be a randomized,
open-label study to determine if bicalutamide improves the rate of clinical improvement in
patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins